

# CITATION REPORT

List of articles citing

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy

DOI: 10.1111/bjd.17245

British Journal of Dermatology, 2019, 181, 580-583.

**Source:** <https://exaly.com/paper-pdf/74817509/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper                                                                                                                                                                                                                                  | IF   | Citations |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 20 | What's the point in checking the skin?. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 445-446                                                                                                                             | 4    |           |
| 19 | Cutaneous Adverse Reactions of Anticancer Agents. <i>Dermatologic Clinics</i> , <b>2019</b> , 37, 555-568                                                                                                                              | 4.2  | 10        |
| 18 | Infliximab/nivolumab/pembrolizumab. <i>Reactions Weekly</i> , <b>2019</b> , 1772, 186-186                                                                                                                                              | 0    |           |
| 17 | Vitiligo-like depigmentation subsequent to subacute cutaneous lupus erythematosus and hydroxychloroquine treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 1470-1473 <sup>2</sup>              | 1.2  | 2         |
| 16 | Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus. <i>Drugs in R and D</i> , <b>2020</b> , 20, 319-330                                                                                             | 3.4  | 7         |
| 15 | Cutaneous Lupus Erythematosus: Progress and Challenges. <i>Current Allergy and Asthma Reports</i> , <b>2020</b> , 20, 12                                                                                                               | 5.6  | 3         |
| 14 | Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1415-1424                                                                            | 4.5  | 18        |
| 13 | Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 263-271                                                               | 4    | 8         |
| 12 | Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-5                                                            | 2.8  | 2         |
| 11 | Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico-pathologic correlation. <i>Journal of Cutaneous Pathology</i> , <b>2021</b> , 48, 789-794 <sup>1</sup> | 1.7  | 1         |
| 10 | Environmental triggers of dermatomyositis: a narrative review. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 434                                                                                                          | 3.2  | 6         |
| 9  | Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2021</b> , 123, 102707                                                                           | 15.5 | 2         |
| 8  | Arzneimittlexantheme unter modernen zielgerichteten Therapien - Immuncheckpoint- und EGFR-Inhibitoren. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1621-1645                                        | 1.2  | 0         |
| 7  | Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19, 1621-1643                                                         | 1.2  | 0         |
| 6  | Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review.. <i>Clinical, Cosmetic and Investigational Dermatology</i> , <b>2022</b> , 15, 51-62                                  | 2.9  | 0         |
| 5  | Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: Pathogenesis, Treatment, and Surveillance.. <i>Cutaneous and Ocular Toxicology</i> , <b>2022</b> , 1-42                                                       | 1.8  | 1         |
| 4  | Interface Dermatitis: Delineating the Diagnosis with Adaptive Immune Markers.. <i>Journal of Cutaneous Pathology</i> , <b>2022</b> ,                                                                                                   | 1.7  |           |

- 3 Mechanisms of dermatologic toxicities to immune checkpoint inhibitor cancer therapies. *Clinical and Experimental Dermatology*, 1.8 0
- 2 Dermatomyositis Triggered by Immune Checkpoint Inhibitors. Three Additional Cases and a Review of the Literature. 0
- 1 Autoimmune skin diseases and Immune Checkpoint Inhibitors. **2023**, 0